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Chemokines are a large family of chemotactic proteins that have a
key role in the immune and inﬂammatory response of various
diseases and disorders including asthma and allergic diseases as well
as autoimmune diseases such as rheumatoid arthritis (RA) [1].
Chemokines control leukocyte activation and immigration to sites of
inﬂammation via interaction with a family of G-protein coupled
receptors (GPCRs). The chemokine receptor type 5 (CCR5) functions
physiologically as a receptor for the leukocyte chemoattractants
RANTES, MIP-1a, and MIP-1b, and it has also recently been indicated
to function physiologically as one of the important cell entry co-
receptors for HIV-1 [2].In lesions of multiple sclerosis (MS), CCR5 has been discovered on
activated myeloid microglial cells and inﬁltrating T cells. CCR5
antagonists therefore might be helpful in suppressing the chronic
inﬂammatory symptoms of this disorder.
Since thediscoveryof CCR5asa co-receptor forHIV-1 cell entry, there
hasbeen an increased attempt in thepharmaceutical industry to develop
CCR5 antagonists [3]. Undeniably, drug development process is often
facedwith the circumstances that a potent ligand should be designed for
a given protein for which no experimentally determined structure is yet
obtained. The most well-known examples are almost certainly the
GPCRs, which have a signiﬁcant role in many biochemical processes.
At present, 50% of all recently developed drugs are targeted against
G-protein coupled receptors [4]. There are strong evidences that all
GPCRs have a common fold [5]. Their general structure is consisting of a
counterclockwise array of seven transmembrane (TM) α-helices of ~25
to 35 residues long (TMs 1 to 7), which extend across the cellular
membrane linkedby three extracellular (EC1 to3) andthree intracellular
loops (IC1 to 3) [6–8]. The N-terminal region of GPCRs, which vary in
length and function, is located on the extracellular part of the lipid
membrane, while the C-terminal region is on the intracellular part.
In order to be suitable for a structure-based drug design process,
the structure of the target protein must be available with a certain
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procedure. For membrane proteins whose crystallization does not
take place as simply as their aqueous counterparts, obtaining a high-
resolution structure is a particularly complicated job. The lipid
environment in the membrane can have a serious impact on the
conformation of the membrane protein [9], and it is not easy to obtain
this ﬁnal conformation via crystallography.
In the lack of an experimentally established crystal structure of a
given protein, homology modeling is the best alternative to construct
a reasonable three-dimensional (3D) model of the target. At present,
homology modeling is the most accurate technique for 3D structure
prediction of proteins [10]. The obtained models will be appropriateable 1
eneral structures and structural details of compounds used in the docking procedure.
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Compound R1 R2 pIC50 ΔG binding
(kcal/mol)
Docking energy
(kcal/mol)
1 OCl 7.85 −5.26 −8.49
2
N
O 8.05 −4.58 −7.45
3 O 8.00 −4.62 −8.14
4 O 7.92 −5.35 −8.22
5 O 8.22 −5.11 −8.34
6 O 8.05 −5.3 −6.34T
Gfor a wide variety of applications, such as structure-based molecular
design and study of mechanism of action of their agonists or
antagonists [11–13]. This method is capable to offer a rational
structural model for a given membrane protein sequence with related
templates sharing more than 25% sequence identity [14,15].
Several studies have been reported on molecular modeling of CCR5.
Huang et al. have constructed CCR5models associated withMIP-1b and
RANTES to explore the residues crucial for the interactionbetweenCCR5
and its natural ligands [16]. In another study, Paterlini et al. constructed
a 3D model of CCR5 to clarify the binding site and selectivity of the
antagonist TAK779 [17]. Arseniev et al. also explored the conformational
characteristics of CCR5 extracellular domain by structural modeling of(continued on next page)
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Compound Ar pIC50 ΔG binding
(kcal/mol)
Docking energy
(kcal/mol)
7
N
7.64 −5.59 −9.1
8
N
7.18 −5.42 −7.2
9 N
N
7.92 −5.25 −7.63
10 7.38 −6 −9.06
11
N
F3C 7.68 −5.68 −8.64
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X
CO2H
Compound Ar X pIC50 ΔG binding
(kcal/mol)
Docking energy
(kcal/mol)
12
N
H 8.41 −5.68 −9.91
13
N
H 8.30 −5.29 −9.43
14
N
N
H 8.18 −5.06 −7.98
15
N
N
F 8.80 −4.82 −8.68
Table 1 (continued)
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Compound Ar R pIC50 ΔG binding
(kcal/mol)
Docking energy
(kcal/mol)
16
N
N
n-C3H7- 8.74 −4.8 −7.89
17
N
N
n-C2H5- 8.82 −4.06 −8.11
18
N
N
8.96 −4.46 −7.87
19
N
N
n-C3H7- 8.77 −4.29 −8.58
20 N
N
n-C3H7- 8.92 −4.76 −8.49
21
N
N
F n-C3H7- 9.40 −4.79 −8.46
22
N
N
F3C n-C3H7- 9.30 −4.59 −7.98
23
N
N
F3C
n-C3H7- 8.92 −4.53 −8.82
24
N
N
MeO
n-C3H7- 9.10 −5.26 −7.27
Table 1 (continued)
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dimensional models of CCR5 using homology modeling approach
followed by 1 nsmolecular dynamics (MD) simulation [19]. A common
shortcoming shared by the above-mentioned studies is that the authors
explored CCR5 structure/functionwithout considering inﬂuence of lipidbilayer on its folding. In other words, MD simulation was carried out
without inserting protein in lipid bilayer. Here in this study, thanks to
modern software and hardware, our primary objective is to investigate
the presence of lipid bilayer in molecular dynamics simulation and its
effects on dynamic behavior of the developed CCR5 model.
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interactions of ligands to a receptor lead to different receptor
conformations [20]. Thus, we faced two challenges: (1) how to
construct the 3Dmodels of the CCR5 receptor; and (2) how to identify
the binding conformations of the receptor in complex with the ligand.
To circumvent these difﬁculties, several modeling and simulation
approaches were utilized in this study. In brief, the computational
steps were as follows:
1. Several 3D models of the CCR5 receptor were built by means of
homology modeling method based on the various alignments and
the X-ray crystal structure of bovine rhodopsin.
2. An initial 20 ns MD simulation was performed on the constructed
CCR5 receptor model inserted in a hydrated POPE (palmitoyloleoyl
phosphatidyl ethanolamine) bilayer.
3. To ﬁnd the possible ligand binding conformation of CCR5, twenty-
four ligandswere docked into the ﬁnal structure extracted from the
MD trajectories of CCR5 by using the molecular docking procedure,
including prediction of the free energy of binding of ligands to the
receptor. The conformation of the most biologically active ligand
was selected as the initial conformation for further simulations.
Among the various conformations of this ligand obtained from the
docking procedure, the conformation with the lowest binding free
energy to CCR5 receptor was chosen.
4. An additional 20 ns MD simulation was performed on the initial
structure of CCR5–ligand complex resulted from the above
docking calculations, embedded in a hydrated POPE bilayer.
Then the resulting ligand–receptor complex was investigated
by analyzing all of the modeling, docking and simulation
results.
It is accepted that a homology model is not the same as an
experimentally determined structure of a given protein. However, it is
still very helpful in assisting us to comprehend the binding modes of
CCR5 and its antagonists. This keeps researchers away from clear
drawbacks in further design procedure by using the combination of
homology modeling and other computational methods. It should be
noted that in the chronological era of development and application of
computational drug design, utilization of available experimentally
determined protein structures is a recently applied tool [21]. Several
studies point out improved performance of a protein structure-based
approach in computational drug design and pharmacophoremodeling
[22,23]. We hope results of the current study shed some light to the
binding mode of CCR5 antagonists for further computational studies.
2. Experimental
2.1. Preparation of data set
All the biological data used here were derived from literature [24].
General chemical structures and the structural details of these
compounds are reported in Table 1. Data are reported as pIC50
(Table 1) for binding versusMIP-1a [25]. pIC50 is the dependent variable
that characterizes the biological parameter for the developed docking
model. The structures of molecules were drawn and optimized using
HyperChem (HyperCube Inc., Gainesville, FL). Semi-empirical AM1
method with Polak–Ribiere algorithm until the root mean square
gradient of 0.01 kcal mol−1 was used as the optimization method.
2.2. Template searching, transmembrane helix prediction and sequence
alignment
The primary sequence of human CCR5 was obtained from SWISS-
PROT database (Accession number P51681) [26]. BLAST (Basic Local
Alignment Search Tool) at NCBI was used to ﬁnd the homologousproteins with known structures to be employed as the template in the
process of CCR5 homology modeling [27].
The crystal structure of bovine rhodopsin (1F88A) at 2.80 Å
resolution was obtained as the modeling template of CCR5 from the
protein data bank [28]. To help deﬁne the transmembrane (TM)
regions, TM helices of bovine rhodopsin structure were assigned using
DSSP [29]. Several helix prediction methods were applied in a direct
manner using their websites to allocate putative TM helix segments of
CCR5 including: MEMSAT 1.5 [30], PORTER [31], SABLE [32], split.
pmfst [33], DOS [34], HMMTOP [35], Mobyle Pasteur [36], OCTOPUS
[37], TMHMM [38], TMpred [39], TOPCONS [40]. After predicting
helices by these servers, a so-called consensus approach was
employed. In this method for each residue, a consensus prediction
was calculated by counting the number of servers that predicted the
residue as being in a helix. For example, consensus 100%was allocated
to a residue that was predicted as helix by all of the 11 servers. The
same procedure was used to predict TM helices of bovine rhodopsin
for comparing with the results of DSSP.
2.3. Homology modeling
In homology modeling step, we would like to look for an ex-
perimentally determined structure of high sequence identity with the
CCR5 receptor. To align the sequence of human CCR5 receptor with
that of bovine rhodopsin, the CLUSTALW program was employed
directly from its website at http://www2.ebi.ac.uk/CLUSTALW [41].
The alignmentwas adjustedmanually based on the results of TM helix
prediction procedure and conserved key residues of GPCRs suggested
by Baldwin et al [6].
MODELLER [42] version 9.2 was used to build homology models of
CCR5 from bovine rhodopsin crystallographic structure. From the
alignments, 3D models containing all non-hydrogen atoms were
obtained automatically using the methods implemented in MOD-
ELLER. From the 1000 model generated with MODELLER for each
alignment, the one corresponding to the lowest value of the
probability density function (pdf) and fewest restraints violations
was selected for further analysis. An ab initiomethod implemented in
the MODELLER that has been demonstrated to predict the conforma-
tions of loop regions was used to reﬁne some of the loops of the
selected model.
The rootmean square deviations (RMSDs) of themodels relative to
the template (1F88) were calculated using MODELLER. The RMSD
differences from template geometry for bond lengths and bond angles
were also calculated using MODELLER. The overall stereochemical
quality of the ﬁnal developed model for each CCR5 model was
assessed by the program PROCHECK [43]. G-factor was calculated for
the developed model using PROCHECK. Environment proﬁle of ﬁnal
developed model was checked using Verify-3D (Structure Evaluation
Server) [44].
2.4. Docking protocol
Docking was performed by AutoDock 4.0 program, using the
implemented empirical free energy function and the Lamarckian
Genetic Algorithm (LGA) [45]. The grid maps were calculated using
AutoGrid. In all dockings, a grid map with 80×80×80 points and a
grid-point spacing of 0.375 Å was applied. Because the location of the
ligand in the complex was known, the maps were centered on the
ligand's binding site on Cα of Phe112. For all docking parameters,
standard values were used as described before [45], except the
amount of independent docking runs performed for each docking
simulation, which was set to 200. Cluster analysis was performed on
the docked results using a root mean square (RMS) tolerance of 0.5 Å,
and the initial coordinates of the ligand were used as the reference
structure.
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Molecular dynamics simulation was performed in two phases. In
the ﬁrst phase, the minimum energy conformation of CCR5 obtained
from protein homology modeling process was used as the starting
structure for MD simulation. The components of the simulation
system were protein, lipid and water. In the second phase, the
obtained conformation of CCR5 from the ﬁrst phase of MD as well as
the docked ligand was employed in the MD simulation process.
All MD simulations were carried out by the GROMACS 4 package
[46] using the ffgmx force ﬁeld (Gromos87). Solvent (i.e. water and
ions), lipid, protein and ligand were coupled separately to a
temperature bath. The lipid bilayer was described using a previously
developed topology ﬁle (Tieleman, see http://moose.bio.ucalgary.ca)
[47]. The best model from homology modeling step was inserted at
the center of the POPE bilayer with its long axis normal to the
membrane–water interface. Theα-helical domain of the receptor was
placed at the same level as the lipid bilayer. Overlapping lipid and
water molecules were discarded to remove overlaps between atoms
of protein and lipids. Water molecules were represented using a
simple point charge (SPC216) model [48]. Thirty Cl− counter-ions
were added by replacing water molecules to ensure the overall charge
neutrality of the simulated system that comprised of CCR5, ligand, 226
POPEs, and 9305 water molecules. Final POPE–CCR5 system was
placed in a box with the dimensions of 96×95×100 (all in Å) with
43412 atoms in total. Periodic boundary conditions were applied in all
three directions of space. The force ﬁeld parameters of ligand were
obtained from PRODRG web server [49]. At ﬁrst, an energy
minimization process was carried out. After energy minimization
process, position restraint procedure was performed in association
with NVT and NPT ensembles.
An NVT ensemble was adopted at constant temperature of 323 K
and with a coupling constant of 0.1 ps with time duration of 100 ps.
After stabilization of temperature an NPT ensemble was performed. In
this phase a constant pressure of 1 bar was employed with a coupling
constant of 5.0 ps with time duration of 1 ns [50]. NPT ensemble was
ﬁnished after pressure stabilization. The coupling scheme of Berend-
sen was employed in both of NVT and NPT ensembles. The particle
mesh Ewald (PME) method interaction was used [51]. A 12 Å cutoff
for long-range and the Lincs algorithm for covalent bond constraints
were applied [52].2.6. Molecular images and evaluation of molecular dynamics
All the molecular images and animations were produced using
VMD and rendered by Tachyon ray tracer [53]. Schematic two-
dimensional representations of the docking results were produced
using LIGPLOT [54]. The trajectories were analyzed using the standard
tools included in the GROMACS distribution. Time interval for RMSD
calculation was 5 ps.Table 2
Locations of the helical TM segments of CCR5 predicted by different commonly used metho
Helix Split.pmfst DOS HMMTOP MEMSAT Mobyle Pasteur OCTOPUS
I 30–57 34–57 36–56 36–56 36–56 33–53
II 65–87 69–86 67–86 67–87 72–92 68–88
III 102–131 103–136 103–124 103–124 104–124 98–128
IV 140–165 143–164 143–167 142–166 141–161 145–165
V 196–223 196–218 198–217 198–218 198–218 196–216
VI 233–263 235–257 235–260 236–257 236–256 236–256
VII 286–301 294–297 291–312 285–301 281–301 278–2983. Results and discussion
3.1. Sequence analysis, helix prediction, and homology modeling
In the homology modeling phase, we look for an experimentally
determined structure of high “sequence identity” with the CCR5. The
building of protein models by homology modeling normally pro-
ceeds along a series of well-deﬁned and commonly accepted steps:
(1) sequence alignment between the target and the template;
(2) building an initialmodel; (3) reﬁning themodel; and (4) evaluating
the quality of the model [12,15].
The crystal structure of A-chain of bovine rhodopsin was the
structurally homologous protein that was found by BLAST analysis
and hence chosen as template for developing the CCR5 model. BLAST
results of CCR5 and bovine rhodopsin showed score of 78.2 and E
value of 5×10−15.
Achieving a high accuracy 3D model of CCR5 using the homology
modeling approach is a very challenging procedure. The reason is the
fact that none of the members of the chemokine receptor class has
been crystallized and no 3D structures of chemokine receptors was
determined experimentally yet. In spite of its low identity with CCR5
(the identity is 20.6%), bovine rhodopsin can be employed as a
template for CCR5. The reason is it belongs to the GPCR family and its
crystal structure exhibits a clear conformational feature of a seven
transmembrane helix bundle, which is a common characteristic in all
GPCRs proteins. In addition, the sequence identity in the transmem-
brane segments between CCR5 and bovine rhodopsin is 30%, which
makes it possible to generate a model. According to a previous study
[55], if two proteins have 30% “segment identity,” then their Cα atoms
are within 3.5 Å of their correct position.
The sequence homology between CCR5 and bovine rhodopsin is
not strong enough for building a model ﬂawlessly. Therefore, to
facilitate describing the TM regions of CCR5, the secondary
structure was predicted by several TM prediction methods. Since
a small number of high-resolution structures are available for such
proteins (0.5% of the PDB entries), the prediction of transmembrane
helices has a signiﬁcant role in the study of membrane proteins.
Here, the prediction methods were utilized against bovine rhodop-
sin with a known 3D structure and CCR5. The distributions of helix
lengths in the two proteins were examined (Table 2) and consensus
8%, 16%, 25%, 50%, 75%, and 100% of methods, which predicted α-
helices for each sequence were assigned (Fig. 1). All of these
methods work with different algorithms and predict different
length and size of helices. As shown in Table 2, all methods
predicted seven TM helices except TMHMM, and TOPCONS, which
predicted 6 TM helices for CCR5. In addition, these methods were
used to predict TM helices of bovine rhodopsin that were somehow
different from DSSP. The 50% consensus for the rhodopsin was
almost in good agreement with DSSP assignment (data was not
shown) and hence was selected for assessment of helices predicted
in the constructed model.ds.
PORTER SABLE TMHMM TMpred TOPCONS Bovine rhodopsin
Crystal structure
(DSSP)
25–57 28–57 34–57 39–56 36–56 34–64
64–91 65–91 68–90 68–87 67–87 71–100
99–130 99–136 105–124 106–124 104–124 106–139
142–165 145–165 144–166 145–165 145–165 150–172
191–223 187–223 199–221 195–215 195–215 196–223
228–260 234–263 234–256 236–256 235–256 243–277
276–315 271–315 281–300 285–321
1...|...10....|...20....|...30....|...40....|...50....|...60....|...70....|...80....|...90....|..100....|..110....|..120....|
Target sequence MDYQVSSPIYDINYYTSEPCQKINVKQIAARLLPPLYSLVFIFGFVGNMLVILILINCKRLKSMTDIYLLNLAISDLFFLLTVPFWAHYAAAQWDFGNTMCQLLTGLYFIGFFSGIFFIILLTID
Cons. | 8 ------------------------HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH------HHHHHHHHHHHHHHHHHHHHHHHHHHHHH-----HHHHHHHHHHHHHHHHHHHHHHHHHHHH
Cons. | 16 ---------------------------HHHHHHHHHHHHHHHHHHHHHHHHHHHHHH-------HHHHHHHHHHHHHHHHHHHHHHHHHHH-------HHHHHHHHHHHHHHHHHHHHHHHHHHH
Cons. | 25 -----------------------------HHHHHHHHHHHHHHHHHHHHHHHHHHHH-------HHHHHHHHHHHHHHHHHHHHHHHHHHH-------HHHHHHHHHHHHHHHHHHHHHHHHHHH
Cons. | 50 ---------------------------------HHHHHHHHHHHHHHHHHHHHHHH----------HHHHHHHHHHHHHHHHHHHHH---------------HHHHHHHHHHHHHHHHHHHHHH-
Cons. | 75 -----------------------------------HHHHHHHHHHHHHHHHHHHHH-----------HHHHHHHHHHHHHHHHHHHH----------------HHHHHHHHHHHHHHHHHHHHH-
Cons. |100 --------------------------------------HHHHHHHHHHHHHHH------------------HHHHHHHHHH--HHH-------------------HHHHHHHHHHHHHHHHHHH-
H-Score | ------------------------11122333466AAABBBBBBBBBBBBBBBAAA5------13369AAABBBBBBBBBBAABBB954431-----1333479ABBBBBBBBBBBBBBBBBBB5
..130....|..140....|..150....|..160....|..170....|..180....|..190....|..200....|..210....|..220....|..230....|..240....|..250
Target sequence RYLAVVHAVFALKARTVTFGVVTSVITWVVAVFASLPGIIFTRSQKEGLHYTCSSHFPYSQYQFWKNFQTLKIVILGLVLPLLVMVICYSGILKTLLRCRNEKKRHRAVRLIFTIMIVYFLFWAP
Cons. | 8 HHHHHHHHHHH---HHHHHHHHHHHHHHHHHHHHHHHHHHHH-------------------HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH----HHHHHHHHHHHHHHHHHHHHHHH
Cons. | 16 HHHHHHHHHHH----HHHHHHHHHHHHHHHHHHHHHHHHHH------------------------HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH---------HHHHHHHHHHHHHHHHHH
Cons. | 25 HHHHHH----------HHHHHHHHHHHHHHHHHHHHHHHHH----------------------------HHHHHHHHHHHHHHHHHHHHHHHHHHH------------HHHHHHHHHHHHHHHHH
Cons. | 50 -----------------HHHHHHHHHHHHHHHHHHHHHHH------------------------------HHHHHHHHHHHHHHHHHHHHHHH----------------HHHHHHHHHHHHHHHH
Cons. | 75 -------------------HHHHHHHHHHHHHHHHHHHHH--------------------------------HHHHHHHHHHHHHHHHHHHH------------------HHHHHHHHHHHHHHH
Cons. |100 --------------------HHHHHHHHHHHHHHH--------------------------------------HHHH-HHHHHHHHHHHH--------------------HHHHHHHHHHHHHHH
H-Score | 55544322222---12467ABBBBBBBBBBBBBBBAAAA941-------------------11112222466ABBBBABBBBBBBBBBBBA9844433----11111246BBBBBBBBBBBBBBB
....|..260....|..270....|..280....|..290....|..300....|..310....|..320....|..330....|..340....|..350..
Target sequence YNIVLLLNTFQEFFGLNNCSSSNRLDQAMQVTETLGMTHCCINPIIYAFVGEKFRNYLLVFFQKHIAKRFCKCCSIFQQEAPERASSVYTRSTGEQEISVGL
Cons. | 8 HHHHHHHHHHHHH-------HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH-------------------------------------
Cons. | 16 HHHHHHHHHHHHH--------------HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH-------------------------------------
Cons. | 25 HHHHHHHHHH-----------------HHHHHHHHHHHHHHHHHHHHHHHH---------------------------------------------------
Cons. | 50 HHHHHHH---------------------------HHHHHHHHHHHHHHHH----------------------------------------------------
Cons. | 75 HHHHHH--------------------------------------HHH-------------------------------------------------------
Cons. |100 HHHHHH------------------------------------------------------------------------------------------------
H-Score | BBBBBB6444222-------111112233355556777776778999876433333333333222-------------------------------------
Fig. 1. Consensus of 8%, 16%, 25%, 50%, 75% and 100% of each residue in CCR5 predicted as helix by 11 different helix prediction methods. Each residue has a score from 1 to 12 based
on how many methods predicted it as helix. A and B in scoring scale are equal to 10, 11.
808 M. Shahlaei et al. / Biochimica et Biophysica Acta 1808 (2011) 802–817The sequence alignment between bovine rhodopsin and human
CCR5 receptor was produced using ClustalW program. Then it was
manually edited according to the known key conserved residues of
the GPCRs family of proteins suggested by Baldwin et al. [6] and TM
helix prediction methods (Fig. 2).
Based on the sequence alignment as an input, the MODELLER
software generates a large number of spatial restraints from the
template structure and constructs a molecular model of the CCR5. The
restraints are usually attained by assuming that the corresponding
distances and angles between aligned residues in the template and
the target proteins are comparable. The output of this process is a
homology model of CCR5.
More than 90% of the members of the class A of GPCRs (rhodopsin
like) have a disulﬁde bridge between the transmembrane helix 3
(TM3) and the extracellular loop 2 (EC2) [56]. However, there are
evidences of a disulﬁde bond between residues Cys101 at the
beginning of TM3 and Cys178 in the middle of extracellular loop 2
(EL2) in CCR5. This disulﬁde bond was made and kept as a constraint
in the homology modeling process.sp|P51681|CCR5_HUMAN MDYQVSSPIYDINYYTS----
sp|P02699|OPSD_BOVIN MNGTEGPNFYVPFSNKTGVVR
*: .. :* .:
sp|P51681|CCR5_HUMAN ILINCKRLKSMTDIYLLNLAI
sp|P02699|OPSD_BOVIN VTVQHKKLRTPLNYILLNLAV
: :: *:*:: : *****:
sp|P51681|CCR5_HUMAN FFSGIFFIILLTIDRYLAVVH
sp|P02699|OPSD_BOVIN GEIALWSLVVLAIERYVVVCK
.:: :::*:*:**:.* :
sp|P51681|CCR5_HUMAN KEGLHYTCSSHFPYSQYQFWK
sp|P02699|OPSD_BOVIN PEGMQCSCGIDYYTPHEETNN
**:: :*. .: .: : :
sp|P51681|CCR5_HUMAN -----KKRHRAVRLIFTIMIV
sp|P02699|OPSD_BOVIN SATTQKAEKEVTRMVIIMVIA
* .:...*::: ::*.
Sp|P51681|CCR5_HUMAN ETLGMTHCCINPIIYAFVGEK
sp|P02699|OPSD_BOVIN AFFAKTSAVYNPVIYIMMNKQ
:. * . **:** ::.::
sp|P51681|CCR5_HUMAN TGEQEISVGL 352
sp|P02699|OPSD_BOVIN TSQVAPA--- 348
*.: :
Fig. 2. CLUSTALW pairwise sequence alignment between the target (CCR5) and template (1
marked using red boxes.The possible applications of generated protein models depend
mainly on the quality of the obtained models. The quality of the
generated model of CCR5 was checked by several methods. To study
the orientation of the helices of CCR5, we overlaid the transmembrane
regions of the generated model with the template. From the obtained
RMSD value (1.87 Å) for CCR5 and rhodopsin, we can deduce that
there is a good agreement between the helices.
Further checked by PROCHECK, the ﬁnal CCR5model indicates that
more than 97% of residue φ–ψ angles are in the favored or additional
allowed regions of Ramachandran plot (Fig. 3A). Again, it indicates
that the ﬁnal obtained 3D model of CCR5 is satisfactory. With respect
to Ramachandran plot, it is observed only three residues are in
disallowed region. Residues located in the unfavorable regions are far
from the substrate-binding domain, indicating that these residues
may not affect the ligand–protein binding simulations.
A parameter produced by PROCHECK indicating the quality of
covalent and bond angle distance is the G-factor. The G–factors were
−0.01°, 0.17° and −0.1° for dihedrals, covalent and in overall,
respectively. The overall main-chain and side-chain parameters, as---EPCQKINVKQIAARLLPPLYSLVFIFGFVGNMLVIL 53
SPFEAPQYYLAEPWQFSMLAAYMFLLIMLGFPINFLTLY 60
*. * .: :*.. *::::** *:*.:
SDLFFLLTVPFWAHYAAAQ--WDFGNTMCQLLTGLYFIG 111
ADLFMVFGGFTTTLYTSLHGYFVFGPTGCNLEGFFATLG 120
:***::: : *:: : : ** * *:* : :*
AVFALKARTVTFGVVTSVITWVVAVFASLPGII-FTRSQ 170
PMSNFRFG-ENHAIMGVAFTWVMALACAAPPLVGWSRYI 179
.: :: ...:: .:***:*: .: * :: ::*
NFQTLKIVILGLVLPLLVMVICYSGILKTLLRCRNE--- 227
ESFVIYMFVVHFIIPLIVIFFCYGQLVFTVKEAAAQQQE 239
: .: :.:: :::**:*:.:**. :: *: .. :
YFLFWAPYNIVLLLNTFQEFFGLNNCSSSNRLDQAMQVT 282
FLICWLPYAGVAFY--------IFTHQGSDFGPIFMTIP 291
::: * ** * : : . ..*: * :.
FRNYLLVFFQKHIAKRFCKCCSIFQQEAPERASSVYTRS 342
FRNCMVTTL----------CCGKNPLGDDEASTTVSKTE 341
*** ::. : **. * :::* . .
F88). The known conserved residues for the GPCRs suggested by Baldwin et al. [6] are
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Fig. 4. The 3D proﬁles of human CCR5model that was generated using Verify-3D server.
Overall compatibility score above zero indicates residues are reasonably folded.
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residues of the model has also been identiﬁed in the viewer. The ﬁnal
step of testing was the packing quality of each residue as evaluated by
the Verify-3D method, which represents the proﬁle achieved with
respect to the residues. The compatibility score above zero in the
Verify-3D graph is corresponding to acceptable side-chain environ-
ments (Fig. 4). This suggests that the model has overall self-
consistency in terms of sequence–structure compatibility.
3.2. MD simulation: Phase I
Clariﬁcation of ligand binding mechanisms is the essential step to
achieve more selective and potent lead compounds for a given target.
To accomplish this goal, we need to construct a model of protein and
then let it feel its natural environment. Molecular dynamic simulation
is one of the best methods for such a reﬁnement. After constructing a
3D structure of CCR5, in order to investigate the conformational
variations of the protein within the hydrated lipid environment, the
MD simulation for this model was performed in an explicit lipid
bilayer environment.
The developed model of CCR5 was inserted in a pre-equilibrated
lipid bilayer consisting of 340 molecules of POPE. Placing of the alpha
helices of CCR5 into the lipid bilayer core was carried out in such a
way that alpha helices were perpendicular to the membrane plane
and protein-overlapping lipids were removed.
In order to impair the incorrect interactions imposed to the 7 TMs
during homology modeling, successive relaxation method was
applied to the POPE–CCR5 system. As a result, constraints between
TM helices were reduced in sequential steps to avoid unwanted
structural drifts during production phase of the MD. The POPE–CCR5
system remained ﬁrm after the relaxation as very slight drift in
energy, temperature, or lipids density was monitored during the MD
(data not shown).
Fig. 5A shows the time history of RMSD for protein structure
immersed in lipid bilayer relative to the starting structure (the output
of the homology modeling process). As it is evident, backbone RMSD
was about 4.7 Å after 20 ns of simulation, and was not increased
signiﬁcantly after 15 ns of simulations. The RMSD value implies that
this protein structure has been affected by its environment dramat-
ically. As it is indicated in Fig. 5A, the protein folding process showsBA
Fig. 3. Ramachandran plot of the φ–ψ distribution of CCR5 produced by PROCHECK (A) after h
[a, b, l, p] additional allowed regions; [~a, ~b, ~l, ~p] generously allowed regions; white aregood reliability since the structures of the developed model are stable
during theMD simulation. Therefore, theMD simulationwas essential
to specify geometry of CCR5 in the vicinity of lipid bilayer. In Fig. 5B
variation in total energy versus time in 20 ns of MD is illustrated,
which shows small ﬂuctuation in the last 5 ns of MD.
Furthermore, the average temperature in 20 ns of MD simulation
at 323 Kwas equal to 323±1.4 K for the investigated system (Fig. 5C).
Therefore, the extracted equilibrium structure at 323 K belonging to
the CCR5 was obtained under stable temperature conditions. These
facts show that energy conservation was satisﬁed in MD simulation.
After structural reﬁnement of CCR5 model by MD simulation in
phase I, the geometric quality of the backbone conformation, namely all
the tests performed in homology modeling step, was carried out again
and the quality of the model was conﬁrmed (data not shown). In brief,
the quality of the backbone geometry of the developed model, the
residue interactions, the residue contacts, and the dynamic stability ofomology modeling and, (B) after MD simulation Phase II. [A, B, L] most favored regions;
as are disallowed regions.
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Passing all the quality assurance tests by the developedmodel, proposes
that this model is a good estimation of CCR5 structure, and can be used
to describe various protein–ligand interactions and to study the
relationship between the structure and function.
3.3. Molecular docking
Molecular docking is the most widespread method for the
calculation of protein–ligand interactions. Molecular docking is an
efﬁcient technique to predict the potential ligand binding site(s) on
the whole protein target. Dynamical studies on binding modes are
essential to elucidate key structural characteristics and interactions
and they provide helpful data for designing effective CCR5 antago-
nists. Hence, in order to explore the predictability as well as the
characteristics of the binding pocket of the developed model and to
make the rational design of novel and more selective antagonists of
CCR5 possible, molecular docking was carried out on CCR5 binding
pocket using a set of CCR5 antagonists shown in Table 1. The 200
docking conformations for each investigated antagonist were sepa-
rated into clusters according to RMSD tolerance of 0.5 Å. As well as
RMSD cluster analysis, AutoDock also uses binding free energy
assessment to assign the best binding conformation. Energies
estimated by AutoDock are described by intermolecular energy(including van der Waals, hydrogen bonding, desolvation, and
electrostatic energies), internal energy, and torsional free energy.
Among these calculated energies by AutoDock, the ﬁrst two provide
the docking energy while the sum of the ﬁrst and the third items
account for the binding energy. Among all interactions occurring in
the active site, the electrostatic interaction between the ligand and the
receptor is themost signiﬁcant, because inmost cases it can assign the
strength of binding and the exact position of the ligand in the active
site [57,58].
Experimental binding afﬁnities (as pIC50 values) and predicted
values (as bindingΔG) by LGA dockings of the 24 compounds of 1,3,4-
trisubstituted pyrrolidine are summarized in Table 1. Investigated
compounds selected for molecular docking have some common
structural features, a pyrrolidine ring in the center of themolecule and
the three side chains (arms) in positions 1, 2 and 4. The CCR5 receptor
is supposed to distinguish these structures and stabilize the ligand
binding. A potential binding site of CCR5 was veriﬁed according to the
previous studies of site-directed mutagenesis [59–62]. The pocket is
located in the extracellular side of the trans-membrane domain and
partly covered by the second extracellular loop (EL2).
The docking results show that all of the studied compounds occupy
an almost similar space in the binding site. The best possible binding
mode of ligand 21 as the most biologically active compound in the
CCR5 active site is illustrated in Fig. 6.
Fig. 6. The structure of compound 21 as the most potent compound in the binding cavity of CCR5. The molecule 21 represented by a stick model inside a solvent excluded surface
(SES) in yellow, and colored by elements.
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and Phe85 in TM2 and Val46 in TM1 assemble one hydrophobic
cluster, which accommodates the 5-ﬂuropyrimidine moiety of the
ligand. In addition, the His315 forms a cation-aromatic interaction
with the carboxylic group of the ligand. It can be seen clearly in the
docking results that the ﬂourobenzene ring of ligand 21 is surrounded
by hydrophobic residues, Leu70 in TM2 and Gly301 in TM7, mainly
through the hydrophobic interaction. In addition, the nitrogen atom of
ﬂuropyrimidne ring forms hydrogen bond to Pro294 as a hydrogen-
bond donor (Fig. 7).
As can be seen in Table 1, among the ﬁrst series of compounds (1–
6), removal of chlorine atom leads to an increase in the activity. This is
probably because of the decrease in steric hindrance and the increase
of interaction between amide group and Tyr251, which improves H-
bond formation. Simple changes in substitutions of pyrrolidine
nitrogen, as with the urea derivative (compound 2), or the cycloalkyl
derivatives (compounds 3 and 4), also provides similar activity.
Comparing the binding modes of docked antagonists conﬁrms that
one arm of these molecules occupies the region within the Glu302,
Gly301 in TM6 and Lue70 and Asn71 in TM2 while the second arm
occupies the area neighboring to the Pro294 and Ilu295 in TM6,Fig 7. Stereoview of the predicted binding site of CCR5 by initial docking. Compound 21 r
elements. Important residues in the pocket are indicated by different colors.Phe112 in TM3 and Ile42 in TM1. The third arm is surrounded by
Met49 and Leu50 in TM1 and Glu302 in TM7.
LIGPLOT software was used to investigate the hydrophobic and
hydrogen bonding interactions to validate the developedmodel of the
interaction between ligand and receptormore. As shown in 2D
schematic interaction model of antagonist 21 with the CCR5 (Fig. 8),
there are hydrophobic interactions between the studied ligand and
CCR5. These interactions exist between Pro70 and Val46 and the
carbon atoms of ﬂuropyrimidine moiety of inhibitor 21, also same
hydrophobic contact exists between carbon atoms of ﬂurobenzene
ring and Gly30 and Glu301, suggesting that more hydrophobic
interactions around this area should improve the inhibitory activities.
There is also a hydrogen bond between antagonist 21 and the Pro294
proposing that more hydrophilic substituents on inhibitors in this
area should increase the activity.
The docking results of other investigated ligands were in
accordance with the obtained results of compound 21. In all docking
results three hydrophilic residues, Arg305, Glu302 and His315 act as
anchors for the carbonyl moiety of ligands and almost in all of them a
hydrogen bond has formed between Pro294 and hydrogen acceptor
atom of ligand.epresented as yellow stick model inside a solvent excluded surface (SES) colored by
Fig. 8. Two-dimensional scheme of interactions between the compound 21 and CCR5 generated by LIGPLOT. Only the more important residues for binding are shown after initial
docking. Brown stickmodels present the important residues in the active site, thick purple stickmodels present the inhibitor, green dotted lines are hydrogen bonds and dashed half-
moons present hydrophobic interactions with the corresponding amino acid residues of CCR5.
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The obtained docking results of CCR5 antagonists allowed us to
propose a general binding mode of these ligands and to determine
residues involved in the ligand recognition. Nevertheless, we decided
to perform a secondMD simulation on the ligand–protein complex for
further investigation of binding modes of ligands and to explain the
effects of ligand binding on the conformation of protein.
Hence, ligand 21–CCR5 complex was selected as a representative
for MD simulation. This complex was used as the starting conforma-
tion for an additional MD run. The aim of the second MD simulation
was to get more precise ligand–receptor models in a state close to the
natural conditions and to explore the binding modes of the ligands
further. Although molecular docking offers reasonable binding
structures for investigated ligands, the MD simulation can account
for even the smallest variances.
One drawback of the MD simulation of proteins in lipid bilayer is
that its success depends on various methodological concepts such as
type of force ﬁeld, types of applied constraints, and the accuracy of
found solution for the equations of motion [63,64]. Especially, amongthese issues the treatment of electrostatic interactions among the
investigated components of the system is worthy to give special
attention [65]. Since lipid biomembrane systems are extremely
charged, lipid molecules are either polar or charged and they interact
with each other, the polar water environment, counterions, and
proteins. Correct treatment of electrostatic interactions in MD
simulations of proteins in the presence of lipid biomembrane is
consequently one of the most signiﬁcant matters in this subject.
Various algorithms are employed to treat electrostatic interactions of
MD simulation of proteins in biomembrane such as the Ewald
summation method, its variants [66], and the fast multiple method
[67]. Especially, the particle-mesh Ewald (PME) technique has been
used increasingly often in biomembrane simulations [68]. Thus, we
employed this algorithm for treating electrostatic interactions among
CCR5, ligand, Cl− as counterion and biomembrane.
The conformational stability of the CCR5–antagonist complex in
the simulation procedure was assessed by carrying out a 20 ns
molecular dynamics simulation of model in a lipid (POPE) bilayer. The
ﬁnal conformation of the CCR5–ligand complex in POPE and water is
illustrated in Fig. 9.
Fig. 9. CCR5–antagonist complex in hydrated POPE lipid bilayer after 20 ns MD simulation in Phase II, lipids in yellow and waters in blue. The front half of the lipid bilayer and two
thirds of waterswere not shown for the sake of clarity. (A) CCR5 receptor appeared as solvent excluded surface (SES), colored by electrostatic potential. (B) CCR5 receptor represented
as ribbon, colored by secondary structure elements.
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the 20 ns MD simulation run. The trajectory stability was checked and
was corroborated by the analysis of RMSD (Fig. 10A), total energy
(Fig. 10B) and temperature (Fig 10C) as functions of time for the CCR5.
Fig. 10A reveals that the RMSD values for the CCR5 has a rising in the
ﬁrst 3000 ps and then stay stable in the rest of the simulation time.
The average RMSD for the CCR5 model when measured from 20 ns
was found to be 0.56±0.03 nm.
The total root mean square ﬂuctuation or RMSF of the peptidic
backbone plus side chains (in solid black), and the RMSF of the
peptidic backbone (N, Cα and C) (in red dashed) were depicted in
Fig. 11 for the developed geometry of CCR5 in lipid bilayer over the
last 5 ns of the simulation. Fig. 11 shows that the residues at N-
terminal and C-terminal regions have more or less equal RMSF values.
It was discovered that during the dynamics simulations very few
ﬂuctuations gone beyond 1 Å and even less ﬂuctuations exceeded
1.5 Å for the total protein. The residues 130–145 with ﬂuctuations
close to 1.8 Å observed in the dynamics plots were located close to the
end of TM3, IL2 and the beginning of TM4, which indicates that these
regions of protein are more unstable than other regions of protein
during MD simulation. It can be seen that the protein–ligand complex
immersed among lipid bilayer and water molecules stays in
equilibrium throughout the entire MD. Then, we deduce that the
MD simulation has constructed an improved and more relaxed
structure of protein and ligand, which can be analyzed for further
studies.
Importantly, simulation of CCR5 both in the presence and the
absence of ligand led to the same ﬁnal peptide conformations and
orientations. There are only slight differences in the backbone
dihedral angle values, and these differences slightly affect the position
of some residues in the Ramachandran plot. As it can be seen in Fig. 3B,
presence of the ligand in the active site of protein during MD
simulation leads to displacement of some residues into the disallowed
regions.
The RMSDof the ligandwas calculated based on theMD simulation of
the system to obtain information on position ﬂuctuations and move-
mentsof ligand's atoms. Fig. 12 shows that theRMSDof the compound21
from the initial conformation, increased to 0.23 Å after 1 ns and then
leveled off to nearly 14 ns. At this point of simulation, RMSD of ligand
dropped suddenly and after about 3 ns rose up again to 0.23 Å andleveled off. This shows that, after 17 ns simulation and preliminary
ﬂuctuations in the magnitude of RMSD of ligand's atoms, the ligand
obtained an equilibrium state characterized by the RMSD proﬁle.
At the end of MD simulation position and orientation of ligand in
the introduced binding site were changed (Fig. 13) and this important
observation indicates useful application of MD simulations after
docking of ligands in the binding site. Explorative runs of molecular
dynamics simulation on the complex between the receptor and the
investigated antagonist revealed that, except for Ile54, His315, Glu302
and Ala298, the rest of residues of active site determined by docking
were changed and some new residues such as Ile56, Phe299 and
Met49 are positioned in proximity of ligands and could participate in
the interaction.
Docking results of the compound 21 to CCR5model showed that at
the end of MD simulation a new hydrogen bonding was found to exist
between docked molecule and Glu302 of CCR5 model and previous
hydrogen bond between ligand and Pro294 was vanished. The new
hydrogen bondwas formed between the nitrogen atom of pyrrolydine
ring of ligand as acceptor and carboxylic group of Glu302 as donor of
hydrogen binding. The compound 21 is also stabilized by hydrophobic
interactions on the two farthest ends of the molecule. On one end, the
propyl group is making stacking interaction with Phe299 as is shown
in the 2D LIGPLOT analyses (Fig. 14). Thus, Phe299may play a key role
in orienting the ligand at the active site by hydrophobic interactions.
This residue does not exist in the binding site of CCR5 recognized by
docking process. Similarly, on the other end, the ﬂorobenzene group is
surrounded by three hydrophobic residues, His315, Ile54 and Phe56.
At the end of MD simulation, the hydrophobic pocket of CCR5, which
appears at the end of docking including Gly30 and Glu301, was
vanished and hydrophobic interactions between ﬂourobenzene ring
of ligand and these residues could not be recognized. The orientation
of the ﬂourobenzene and ﬂouropyrimidine rings of the compound 21
was not similar in binding modes after molecular docking and MD
simulation. These results reveal that MD simulation obligate ligand to
optimize its orientation and distance to binding site for maximum
interaction with receptor. On docking of this ligand with CCR5, the
lowest energy conformation did not show any interaction with the
His315 and Phe299 side chains due to the absence of appropriate
orientation and distance as was observed at the end of MD simulation
with CCR5.
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In this work, homology modeling, molecular docking and
molecular dynamics simulation were performed to explore structural
features and binding mechanism of some inhibitors of CCR5, and to
construct a model for designing new CCR5 inhibitors effective in
preventing HIV attachment to the host cell.R
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Fig 13. Stereoview of the binding site of CCR5 after MD simulation Phase II. Compound 21 represented as yellow stick model inside a solvent excluded surface (SES) colored by
elements. Important residues in the pocket are indicated by different colors.
Fig. 14. Intermolecular interactions of compound 21 with CCR5 in 2D ﬂattened space after MD simulation Phase II.
815M. Shahlaei et al. / Biochimica et Biophysica Acta 1808 (2011) 802–817
816 M. Shahlaei et al. / Biochimica et Biophysica Acta 1808 (2011) 802–817The obtained docking results of CCR5 antagonists allowed us to
propose a general binding mode of these ligands to this receptor and to
determine residues involved in the ligand recognition. For further
investigation of binding modes of ligands and to explain the effects of
ligand binding on protein conformation, we decided to perform a
secondmolecular dynamics simulation on the ligand–protein complex.
At the end of the MD simulation, a change in the position and
orientation of the ligand in binding site was observed. This important
observation indicated that the application of MD simulation after
docking of ligands was useful. Explorative runs of molecular dynamics
simulation on the receptor–ligand complex revealed that except for
Ile54, His315, Glu302 and Ala298, the rest of residues in the active site
determined by docking were changed and some new residues such as
Ile56, Phe299 and Met49 were positioned in proximity of the ligands
and could participate in the interaction.
Acknowledgments
Financial supporting of this project by a research grant (No. 289170)
from the Isfahan Pharmaceutical Sciences ResearchCenter of the Isfahan
University of Medical Sciences is acknowledged.
References
[1] R.G. Wei, D.O. Arnaiz, Y.L. Chou, D. Davey, L. Dunning, W. Lee, S.F. Lu, J. Onuffer, B.
Ye, G. Phillips, CCR5 receptor antagonists: discovery and SAR study of
guanylhydrazone derivatives, Bioorg. Med. Chem. Lett. 17 (2007) 231–234.
[2] M.P. Dsouza, V.A. Harden, Chemokines and HIV-1 second receptors—conﬂuence of
two ﬁelds generates optimism in AIDS research, Nat. Med. 2 (1996) 1293–1300.
[3] A. Palani, S. Shapiro, J.W. Clader, W.J. Greenlee, S. Vice, S. McCombie, K. Cox, J.
Strizki, B.M. Baroudy, Oximino-piperidino-piperidine-based CCR5 antagonists.
Part 2: synthesis, SAR and biological evaluation of symmetrical heteroaryl
carboxamides, Bioorg. Med. Chem. Lett. 13 (2003) 709–712.
[4] T. Klabunde, G. Hessler, Drug design strategies for targeting G-protein-coupled
receptors, Chembiochem 3 (2002) 929–944.
[5] U. Gether, Uncovering molecular mechanisms involved in activation of G protein-
coupled receptors, Endocr. Rev. 21 (2000) 90–113.
[6] J.M. Baldwin, G.F.X. Schertler, V.M. Unger, An alpha-carbon template for the
transmembrane helices in the rhodopsin family of G-protein-coupled receptors,
J. Mol. Biol. 272 (1997) 144–164.
[7] K. Palczewski, G protein-coupled receptor rhodopsin, Annu. Rev. Biochem. 75
(2006) 743–767.
[8] V. Cherezov, D.M. Rosenbaum, M.A. Hanson, S.G.F. Rasmussen, F.S. Thian, T.S.
Kobilka, H.J. Choi, P. Kuhn, W.I. Weis, B.K. Kobilka, R.C. Stevens, High-resolution
crystal structure of an engineered human beta(2)-adrenergic G protein-coupled
receptor, Science 318 (2007) 1258–1265.
[9] A. Ivetac, M.S.P. Sansom, Molecular dynamics simulations and membrane protein
structure quality, Eur. Biophys. J. Biophys. Lett. 37 (2008) 403–409.
[10] L. Bordoli, F. Kiefer, K. Arnold, P. Benkert, J. Battey, T. Schwede, Protein structure
homology modeling using SWISS-MODEL workspace, Nat. Protoc. 4 (2009) 1–13.
[11] T. Yoneda, S. Yoneda, N. Takayama, M. Kitazawa, H. Umeyama, A homology
modeling method of an icosahedral viral capsid: inclusion of surrounding protein
structures, Journal of Molecular Graphics & Modelling 17 (1999) 114.
[12] K. Ginalski, Comparative modeling for protein structure prediction, Curr. Opin.
Struct. Biol. 16 (2006) 172–177.
[13] M.Y. Li, B.H. Wang, Homology modeling and examination of the effect of the D92E
mutation on the H5N1 nonstructural protein NS1 effector domain, J. Mol. Model.
13 (2007) 1237–1244.
[14] A. Tramontano, Homology modeling with low sequence identity, Meth.
Companion Meth. Enzymol. 14 (1998) 293–300.
[15] L.R. Forrest, C.L. Tang, B. Honig, On the accuracy of homology modeling and
sequence alignment methods applied to membrane proteins, Biophys. J. 91
(2006) 508–517.
[16] N.M. Zhou, Z.W. Luo, J.W. Hall, J.S. Luo, X.B. Han, Z.W. Huang, Molecular modeling
and site-directed mutagenesis of CCR5 reveal residues critical for chemokine
binding and signal transduction, Eur. J. Immunol. 30 (2000) 164–173.
[17] M.G. Paterlini, Structure modeling of the chemokine receptor CCR5: implications
for ligand binding and selectivity, Biophys. J. 83 (2002) 3012–3031.
[18] R.G. Efremov, F. Legret, G. Vergoten, A. Capron, G.M. Bahr, A.S. Arseniev, Molecular
modeling of HIV-1 coreceptor CCR5 and exploring of conformational space of its
extracellular domain in molecular dynamics simulation, J. Biomol. Struct. Dyn. 16
(1998) 77–90.
[19] S.Q. Liu, X.F. Shi, C.Q. Liu, Z.R. Sun, Characterize dynamic conformational space of
human CCR5 extracellular domain by molecular modeling and molecular
dynamics simulation, J. Mol. Struct. THEOCHEM 673 (2004) 133–143.
[20] J.J. Kulagowski, H.B. Broughton, N.R. Curtis, I.M. Mawer, M.P. Ridgill, R. Baker, F.
Emms, S.B. Freedman, R. Marwood, S. Patel, C.I. Ragan, P.D. Leeson, 3–4-(4-
chlorophenyl)piperazin-1-yl methyl-1H-pyrrolo 2, 3-b pyridine: an antagonistwith high afﬁnity and selectivity for the human dopamine D-4 receptor, J. Med.
Chem. 39 (1996) 1941–1942.
[21] O.F. Guner, History and evolution of the pharmacophore concept in computer-
aided drug design, Curr. Top. Med. Chem. 2 (2002) 1321–1332.
[22] T. Steindl, T. Langer, Inﬂuenza virus neuraminidase inhibitors: generation and
comparison of structure-based and common feature pharmacophore hypotheses
and their application in virtual screening, J. Chem. Inf. Comput. Sci. 44 (2004)
1849–1856.
[23] M. Rella, C.A. Rushworth, J.L. Guy, A.J. Turner, T. Langer, R.M. Jackson, Structure-
based pharmacophore design and virtual screening for novel angiotensin
converting enzyme 2 inhibitors, J. Chem. Inf. Model. 46 (2006) 708–716.
[24] C.A. Willoughby, K.G. Rosauer, J.J. Hale, R.J. Budhu, S.G. Mills, K.T. Chapman, M.
MacCoss, L. Malkowitz, M.S. Springer, S.L. Gould, J.A. DeMartino, S.J. Siciliano, M.A.
Cascieri, A. Carella, G. Carver, K. Holmes, W.A. Schleif, R. Danzeisen, D. Hazuda, J.
Kessler, J. Lineberger, M. Miller, E.A. Emini, 1, 3, 4 trisubstituted pyrrolidine CCR5
receptor antagonists bearing 4-aminoheterocycle substituted piperidine side
chains, Bioorg. Med. Chem. Lett. 13 (2003) 427–431.
[25] D.J. Hazuda, P. Felock, M. Witmer, A. Wolfe, K. Stillmock, J.A. Grobler, A. Espeseth,
L. Gabryelski, W. Schleif, C. Blau, M.D. Miller, Inhibitors of strand transfer that
prevent integration and inhibit HIV-1 replication in cells, Science 287 (2000)
646–650.
[26] E. Gasteiger, A. Gattiker, C. Hoogland, I. Ivanyi, R.D. Appel, A. Bairoch, ExPASy: the
proteomics server for in-depth protein knowledge and analysis, Nucleic Acids Res.
31 (2003) 3784–3788.
[27] S.F. Altschul, T.L. Madden, A.A. Schaffer, J.H. Zhang, Z. Zhang, W. Miller, D.J.
Lipman, Gapped BLAST and PSI-BLAST: a new generation of protein database
search programs, Nucleic Acids Res. 25 (1997) 3389–3402.
[28] H.M.Berman, J.Westbrook, Z. Feng,G.Gilliland, T.N. Bhat,H.Weissig, I.N. Shindyalov,
P.E. Bourne, The Protein Data Bank, Nucleic Acids Res. 28 (2000) 235–242.
[29] W. Kabsch, C. Sander, Dictionary of protein secondary structure—pattern-
recognition of hydrogen-bonded and geometrical features, Biopolymers 22
(1983) 2577–2637.
[30] D.T. Jones, W.R. Taylor, J.M. Thorton, A model recognition approach to the
prediction of all-helical membrane–protein structure and topology, Biochemistry
33 (1994) 3038–3049.
[31] G. Pollastri, A. McLysaght, Porter: a new, accurate server for protein secondary
structure prediction, Bioinformatics 21 (2005) 1719–1720.
[32] R. Adamczak, A. Porollo, J. Meller, Combining prediction of secondary structure
and solvent accessibility in proteins, Proteins: Struct., Funct., Bioinf. 59 (2005)
467–475.
[33] D. Juretic, A. Jeroncic, D. Zucic, Sequence analysis of membrane proteins with the
Web server SPLIT, Croat. Chem. Acta 72 (1999) 975–997.
[34] M. Cserzo, E. Wallin, I. Simon, G. vonHeijne, A. Elofsson, Prediction of
transmembrane alpha-helices in prokaryotic membrane proteins: the dense
alignment surface method, Protein Eng. 10 (1997) 673–676.
[35] G.E. Tusnady, I. Simon, The HMMTOP transmembrane topology prediction server,
Bioinformatics 17 (2001) 849–850.
[36] B. Neron, H. Menager, C. Maufrais, N. Joly, J. Maupetit, S. Letort, S. Carrere, P.
Tuffery, C. Letondal, Mobyle: a new full web bioinformatics framework,
Bioinformatics 25 (2009) 3005–3011.
[37] H. Viklund, A. Elofsson, OCTOPUS: improving topology prediction by two-track
ANN-based preference scores and an extended topological grammar, Bioinfor-
matics 24 (2008) 1662–1668.
[38] K. Melen, A. Krogh, G. von Heijne, Reliability measures for membrane protein
topology prediction algorithms, J. Mol. Biol. 327 (2003) 735–744.
[39] K. Hofmann, W. Stoffel, TMbase: a database of membrane spanning proteins, Biol.
Chem. Hoppe Seyler 347 (1993) 166.
[40] A. Bernsel, H. Viklund, A. Hennerdal, A. Elofsson, TOPCONS: consensus prediction
of membrane protein topology, Nucleic Acids Res. 37 (2009) W465–W468.
[41] J.D. Thompson, D.G. Higgins, T.J. Gibson, Clustal-W - improving the sensitivity of
progressive multiple sequence alignment through sequence weighting, position-
speciﬁc gap penalties and weight matrix choice, Nucleic Acids Res. 22 (1994)
4673–4680.
[42] A. Sali, T.L. Blundell, Comparative protein modeling by satisfaction of spatial
restraints, J. Mol. Biol. 234 (1993) 779–815.
[43] R.A. Laskowski, M.W. Macarthur, D.S. Moss, J.M. Thornton, Procheck—a program
to check the stereochemical quality of protein structures, J. Appl. Crystallogr. 26
(1993) 283–291.
[44] R. Luthy, J.U. Bowie, D. Eisenberg, Assessment of protein models with 3-
dimensional proﬁles, Nature 356 (1992) 83–85.
[45] G.M. Morris, D.S. Goodsell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, A.J. Olson,
Automated docking using a Lamarckian genetic algorithm and an empirical
binding free energy function, J. Comput. Chem. 19 (1998) 1639–1662.
[46] D. Van der Spoel, E. Lindahl, B. Hess, G. Groenhof, A.E. Mark, H.J.C. Berendsen,
GROMACS: fast, ﬂexible, and free, J. Comput. Chem. 26 (2005) 1701–1718.
[47] D.P. Tieleman, J.L. MacCallum, W.L. Ash, C. Kandt, Z.T. Xu, L. Monticelli, Membrane
protein simulations with a united-atom lipid and all-atom protein model: lipid–
protein interactions, side chain transfer free energies and model proteins, J. Phys.
Condens. Matter 18 (2006) S1221–S1234.
[48] L. Rivail, C. Chipot, B. Maigret, I. Bestel, S. Sicsic, M. Tarek, Large-scale molecular
dynamics of a G protein-coupled receptor, the human 5-HT4 serotonin receptor,
in a lipid bilayer, J. Mol. Struct. Theochem. 817 (2007) 19–26.
[49] D.M.F. van Aalten, R. Bywater, J.B.C. Findlay, M. Hendlich, R.W.W. Hooft, G. Vriend,
PRODRG, a program for generating molecular topologies and unique molecular
descriptors from coordinates of small molecules, Journal of Computer-Aided
Molecular Design 10 (1996) 255–262.
817M. Shahlaei et al. / Biochimica et Biophysica Acta 1808 (2011) 802–817[50] H.J.C. Berendsen, J.P.M. Postma,W.F. Van Gunsteren, A. Dinola, J.R. Haak, Molecular
dynamics with coupling to an external bath, J. Chem. Phys. 81 (1984) 3684–3690.
[51] T. Darden, D. York, L. Pedersen, Particle mesh ewald—an n.log(n) method for
ewald sums in large systems, J. Chem. Phys. 98 (1993) 10089–10092.
[52] B. Hess, H. Bekker, H.J.C. Berendsen, J. Fraaije, LINCS: a linear constraint solver for
molecular simulations, J. Comput. Chem. 18 (1997) 1463–1472.
[53] W. Humphrey, A. Dalke, K. Schulten, VMD: visual molecular dynamics, Journal of
Molecular Graphics 14 (1996) 33.
[54] A.C. Wallace, R.A. Laskowski, J.M. Thornton, Ligplot—a program to generate
schematic diagrams of protein ligand interactions, Protein Eng. 8 (1995) 127–134.
[55] R. Sanchez, A. Sali, Comparative protein structure modeling in genomics,
J. Comput. Phys. 151 (1999) 388–401.
[56] A. Gonzalez, L.S. Duran, R. Araya-Secchi, J.A. Garate, C.D. Pessoa-Mahana, C.F.
Lagos, T. Perez-Acle, Computational modeling study of functional microdomains
in cannabinoid receptor type 1, Bioorg. Med. Chem. 16 (2008) 4378–4389.
[57] D.M. Garrido, D.F. Corbett, K.A. Dwornik, A.S. Goetz, T.R. Littleton, S.C. McKeown,
W.Y. Mills, T.L. Smalley, C.P. Briscoe, A.J. Peat, Synthesis and activity of small
molecule GPR40 agonists, Bioorg. Med. Chem. Lett. 16 (2006) 1840–1845.
[58] S.C. McKeown, D.F. Corbett, A.S. Goetz, T.R. Littleton, E. Bigham, C.P. Briscoe, A.J.
Peat, S.P. Watson, D.M.B. Hickey, Solid phase synthesis and SAR of small
molecule agonists for the GPR40 receptor, Bioorg. Med. Chem. Lett. 17 (2007)
1584–1589.
[59] T. Dragic, A. Trkola, D.A.D. Thompson, E.G. Cormier, F.A. Kajumo, E. Maxwell, S.W.
Lin, W.W. Ying, S.O. Smith, T.P. Sakmar, J.P. Moore, A binding pocket for a small
molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5,
Proc. Natl Acad. Sci. USA 97 (2000) 5639–5644.
[60] L.A. Castonguay, Y.M. Weng, W. Adolfsen, J. Di Salvo, R. Kilburn, C.G. Caldwell, B.L.
Daugherty, P.E. Finke, J.J. Hale, C.L. Lynch, S.G. Mills, M. MacCoss, M.S. Springer, J.A.DeMartino, Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1, 3, 4-trisub-
stituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis
study the binding pocket, Biochemistry 42 (2003) 1544–1550.
[61] F. Tsamis, S. Gavrilov, F. Kajumo, C. Seibert, S. Kuhmann, T. Ketas, A. Trkola, A.
Palani, J.W. Clader, J.R. Tagat, S. McCombie, B. Baroudy, J.P. Moore, T.P. Sakmar, T.
Dragic, Analysis of the mechanism by which the small-molecule CCR5 antagonists
SCH-351125 and SCH-350581 inhibit human immunodeﬁciency virus type 1
entry, J. Virol. 77 (2003) 5201–5208.
[62] C. Govaerts, A. Bondue, J.Y. Springael, M. Olivella, X. Deupi, E. Le Poul, S.J. Wodak,
M. Parmentier, L. Pardo, C. Blanpain, Activation of CCR5 by chemokines involves
an aromatic cluster between transmembrane helices 2 and 3, J. Biol. Chem. 278
(2003) 1892–1903.
[63] D.P. Tieleman, S.J. Marrink, H.J.C. Berendsen, A computer perspective of
membranes: molecular dynamics studies of lipid bilayer systems, Biochim.
Biophys. Acta, Rev. Biomembr. 1331 (1997) 235–270.
[64] W.F. van Gunsteren, A.E. Mark, Validation of molecular dynamics simulation,
J. Chem. Phys. 108 (1998) 6109–6116.
[65] J. Norberg, L. Nilsson, On the truncation of long-range electrostatic interactions in
DNA, Biophys. J. 79 (2000) 1537–1553.
[66] C. Sagui, T.A. Darden, Molecular dynamics simulations of biomolecules: long-
range electrostatic effects, Annu. Rev. Biophys. Biomol. Struct. 28 (1999)
155–179.
[67] L. Greengard, V. Rokhlin, A fast algorithm for particle simulations (Reprinted from
the Journal of Computational Physics, vol 73, pg 325-348, 1987), J. Comput. Phys.
135 (1997) 280–292.
[68] R.M. Venable, B.R. Brooks, R.W. Pastor, Molecular dynamics simulations of gel
(L-beta I) phase lipid bilayers in constant pressure and constant surface area
ensembles, J. Chem. Phys. 112 (2000) 4822–4832.
